2013
Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer.
Galsky M, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh W, Bamias A. Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer. Journal Of Clinical Oncology 2013, 31: 251-251. DOI: 10.1200/jco.2013.31.6_suppl.251.Peer-Reviewed Original ResearchProgression-free-survivalFirst-line cisplatin-based chemotherapyMetastatic urothelial cancerCisplatin-based chemotherapyFirst-line treatmentOverall survivalUrothelial cancerMetastatic UCLandmark analysisTreatment of metastatic urothelial cancerMedian progression-free-survivalPresence of visceral metastasesProgression-free survivalPhase II trialAnalysis of patientsShorter response durationLead-time biasProportional hazards modelMedian OSVisceral metastasesII trialIII trialsNovel regimensPredicting OSFirst-line
2000
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.
Kaufman D, Raghavan D, Carducci M, Levine E, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. Journal Of Clinical Oncology 2000, 18: 1921-7. PMID: 10784633, DOI: 10.1200/jco.2000.18.9.1921.Peer-Reviewed Original ResearchConceptsMetastatic urothelial cancerTreatment of metastatic urothelial cancerChemotherapy-naive patientsUrothelial cancerMedian time to treatment failurePhase II trial of gemcitabineTreatment of chemotherapy-naive patientsDay 1Time to treatment failureStage IV carcinomaTrial of gemcitabineCombination of gemcitabinePhase II trialClinical safety profileHematologic toxicityCisplatin doseIV carcinomaPartial responseMedian survivalTreatment failureSafety profileSevere toxicityGemcitabineChemotherapeutic agentsDisease progression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply